We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • Cardiovascular
  • Incretins
  • Insulin
  • SGLT2
  • T2 Diabetes
  • Diabetes
  • Blog

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • Cardiovascular
  • Incretins
  • Insulin
  • SGLT2
  • T2 Diabetes
  • Diabetes
  • Blog

SUBSCRIBE: eNewsletter

Empagliflozin Lowered BP in Patients with T2DM and Hypertension

  • Leah Lawrence
Nov 5, 2014
  • SGLT2, Hypertension, T2 Diabetes
Empagliflozin lowers blood pressure

The sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin significantly reduced HbA1c, systolic and diastolic blood pressure levels in patients with type 2 diabetes and hypertension compared with placebo, according to the results of a study published recently in Diabetes Care.

The FDA recently approved empagliflozin as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2DM). Although clinical trials have shown that the drug is associated with decreases in systolic blood pressure, it is not approved as an antihypertensive agent.

Researchers led by Ilkka Tikkanen, MD, of the department of medicine at Helsinki University Central Hospital and Minerva Institute for Medical Research, Finland, conducted the EMPA-REG BP trial to assess the effects of 12 weeks of 10-mg and 25-mg empagliflozin on blood pressure and glycemic control in patients with T2DM and hypertension.

Researchers defined hypertension as a mean seated office systolic pressure of 130 to 159 mm Hg and diastolic pressure of 80 to 99 mm Hg. All patients were aged 18 years or older, had a body mass index of 45 kg/m2 or less, and had uncontrolled T2DM with an HbA1c of 7% to 10%. In addition, patients had to be on as many as two antihypertensive medications at the time of screening and during a 2-week, placebo run-in period.

The study included 825 patients who were randomly assigned to receive either 10-mg empagliflozin, 25-mg empagliflozin, or placebo once daily for 12 weeks.

At 12 weeks, patients in both the 10- and 25-mg empagliflozin groups had significant reductions in 24-hour ambulatory blood pressure monitoring (ABPM) levels compared with placebo. According to the researchers, they used ABPM to avoid any “white coat” effect seen with taking blood pressure measurements while in a physician’s office.

Patients assigned the empagliflozin 10-mg dose had an adjusted mean difference in 24-hour systolic blood pressure versus placebo of –3.44 mm Hg, and patients assigned the 25-mg dose, a difference of –4.16 mm Hg (P<.001 for both). Similarly, the adjusted mean difference versus placebo at 12 weeks for diastolic pressure was a decrease of 1.36 mm Hg for 10-mg empagliflozin and a decrease of 1.72 mm Hg for 25-mg empagliflozin (P<.001 for both).

Those patients with an ABPM level greater than 130/80 mm Hg at baseline had greater reduction in blood pressure compared with patients with a baseline ABPM of less than 130/80 mm Hg.

As seen in previous trials that have looked at glycemic control associated with empagliflozin, patients assigned the study drug also had significant reductions in HbA1c at 12 weeks. Compared with placebo, patients assigned the 10-mg dose had a mean 0.62% reduction in HbA1c, and those assigned the 25-mg dose had a mean 0.65% reduction (P<.001 for both).

In their discussion of the results, the researchers noted that it is not yet fully known the mechanism by which empagliflozin reduces blood pressure.

As part of its approval, the FDA required that cardiovascular outcomes associated with empagliflozin be examined further. The ongoing EMPA-REG OUTCOME trial is expected to provide physicians with more information about the safety of empagliflozin on cardiovascular and microvascular outcomes in patients with T2DM who are at high cardiovascular risk.

References: 

Tikkanen I, Narko K, Zeller C, et al on behalf of the EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2014;doi:10.2337/dc14-1096.

Related Articles

  • Adding Pounds in Adulthood Ups Major Health Risks
  • Hemopericardium and Tamponade
  • Syncope and Sweat in a 65-Year-Old Man
  • 5 Top Hypertension Apps for Primary Care
  • Hypertension Still a High-wire Act: 8 New Studies

Resource Topics rightRail

  • Resource Topics
  • Partner Content
ENDO 2017
There is currently no available content. Please check back soon.
Connect with Us
  • Twitter
  • Facebook
  • Google+
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.